Immunotherapy Laboratory, Carmel Medical Center, Haifa, Israel.
The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Front Immunol. 2019 Aug 8;10:1924. doi: 10.3389/fimmu.2019.01924. eCollection 2019.
Most cancer peptide vaccinations tested so far are capable of eliciting a strong immune response, but demonstrate poor clinical benefits. Since peptide vaccination is safe and well-tolerated, and several indications suggest that it has clear potential advantages over other modalities of treatment, it is important to investigate the reasons for these clinical failures. In this review, the current state of the art in targeting angiogenic proteins via peptide vaccines is presented, and the underlying reasons for both the successes and the failures are analyzed. The review highlights a number of areas critical for future success, including choice of target antigens, types of peptides used, delivery methods and use of proper adjuvants, and suggests ways to achieve better clinical results in the future.
迄今为止，大多数经测试的癌症肽疫苗都能够引发强烈的免疫反应，但临床获益不佳。由于肽疫苗安全且耐受性良好，并且有几项适应证表明其比其他治疗方式具有明显优势，因此，研究这些临床失败的原因很重要。在本文中，介绍了通过肽疫苗靶向血管生成蛋白的最新技术现状，并分析了成功和失败的根本原因。本文重点介绍了一些未来成功的关键领域，包括靶抗原的选择、使用的肽类型、传递方法和适当佐剂的使用，并提出了未来实现更好临床效果的方法。
